chronic heart failure with preserved ejection fraction
Conditions
Interventions
placebo:placebo
Sponsors
The First Affiliated Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. aged 18~70 years; 2. with a history of symptomatic chronic heart failure of at least 3months(NYHA class II or III), to receive the optimal treatment and to be in a stable clinical condition; 3. EF%=50%; 4. at least one predefined echocardiographic criterion related to diastolic dysfunction as evaluated by the investigating site (1) echo-Doppler E/e' ratio of >13; (2) e' lateral 34mL/m2 E/e' =ratio of peak early diastolic mitral flow velocity divided by the mean of the annular lateral (e' lateral) and septal (e' septal) velocities 5. patient enrollment were exercise capacity 13; (2) e' lateral 34mL/m2 E/e' =ratio of peak early diastolic mitral flow velocity divided by the mean of the annular lateral (e' lateral) and septal (e' septal) velocities 5. patient enrollment were exercise capacity <80% of age-predicted and sex-predicted normal ranges in Cardiopulmonary Exercise Testing.
Exclusion criteria
Exclusion criteria: 1. severe valvular disease, primary hypertrophic or restrictive cardiomyopathy and systemic illness associated with infiltrative heart disease; 2. permanent atrial fibrillation or recent (160mmHgordiastolicbloodpressure >100mmHg) 4. Treatments not allowed at inclusion and during the study included non-dihydropyridine calcium channel blockers, class I anti-arrhythmics and strong inhibitors of cytochrome P450 3A4 5. heart rate 160mmHgordiastolicbloodpressure >100mmHg) 4. Treatments not allowed at inclusion and during the study included non-dihydropyridine calcium channel blockers, class I anti-arrhythmics and strong inhibitors of cytochrome P450 3A4 5. heart rate <60 beats/min; sick sinus syndrome; second-degree and third-degree atrioventricular block; 6. established or suspected pulmonary diseases,sever joint-associated disease,COPD,pulmonary hypertension; 7. ACS in recent two months or coronary revascularization in recent six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VO2 peak;;VO2 peak; | — |
Countries
China
Contacts
Public ContactHuang Huiling;Huang Huiling ;
;
Outcome results
None listed